Proteorex is a biotechnology startup spun out by Structural Genomics Consortium, leaders in the field of epigenetics research. Proteorex Therapeutics has two drug research programs to target a very rare type of Acute Myeloid Leukemia (AML) termed r-All/AML. This affects infants under the age of 1 year, kids under the age of 17 years and certain adult populations too. Currently, there are no treatments in the market. The existing Leukemia drugs are either ineffective for this subtype or very toxic. Proteorex has developed and validated a novel technology platform that enabled us to find novel leads for these two r-MLL drug targets. Our business model is to use our technology platform to find drugs against some of these rare cancers and work towards personalized cancer medicine via internal discovery and strategic partnerships which pharmaceutical companies. We will generate a pipeline of first-in-class and best-in-class products and find an exit via acquisition or IPO by year 5.